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Abstract
Objective: To analyse the effect of differentiation on disease-free survival (DFS) and overall survival (OS) in patients with stage I
adenocarcinoma of the endometrium. Patients and methods: From 1979 to 1995, 350 patients with FIGO stage IA–IC with well (G1),
moderately (G2) or poorly (G3) differentiated tumors were treated with surgery and high dose-rate brachytherapy with or without external
radiation. Median age was 65 years (39–86 years). Results: The 5-year DFS was 8863% for the G1 tumors, 7764% for the G2 tumors,
and 6767% for the G3 tumors (P50.0049). With regard to the events contributing to DFS, the 5-year cumulative percentage of local
relapse was 4.6% for the G1 tumors, 9.0% for the G2 tumors, and 4.6% (P50.027) for the G3 tumors. Cumulative percentage of
metastasis was 1.4, 6.3 and 7.2% (P,0.001), respectively, whereas percentages of death were 6.0, 7.9 and 20.7% (P,0.001). The 5-year
OS was 9163, 8364 and 7667%, respectively (P50.0018). In terms of multivariate hazard ratios (HR), the relative differences between
the three differentiation groups correspond to an increase of 77% of the risk of occurrence of either of the three events considered for the
DFS (HR51.77, 95% Cl [0.94–3.33]), (P50.078) for the G2 tumors and of 163% (HR52.63, 95% Cl [1.27–5.43]), (P50.009) for the
G3 tumors with respect to the G1 tumors. The estimated relative hazards for OS are, respectively, in line with those for DFS: HR51.51
(P50.282) for the G2 tumors; and HR53.37 (P50.003) for the G3 tumors. Conclusion: Patients with grade 1 tumors are those least
exposed to either local relapse, metastasis, or death. In contrast patients with grade 2 tumors seem to be at higher risk of metastasis,
whereas patients with grade 3 tumors appear at higher risk of death. Since we have looked at the first of three competing events (local
relapse, metastasis and death), this suggests that patients with grade 3 tumors probably progress to death so fast that local relapse, if any,
cannot be observed. Ó 2000 Elsevier Science Ireland Ltd. All rights reserved.
1. Introduction based on the myometrial invasion only, independently of
cell differentiation.
Cell differentiation has been shown to be one of the
most important prognostic factors in carcinoma of the
endometrium [1–4]. In this retrospective analysis we 2. Patients and methods
aimed to investigate the effect of grade on disease control
in FIGO stage I patients [5], who were treated with a 2.1. Patient population
combination of surgery and postoperative radiotherapy
From April 1979 to December 1995, 350 patients with
primary FIGO stage IA–IC pure adenocarcinoma of the
*Corresponding author. Tel.: 141-21-3143269; fax: 141-21-3143263. endometrium were treated in the Centre Hospitalier Uni-
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Table 1 local recurrence, metastasis or death, whichever occurred
Patients characteristics first. The secondary end-point was overall survival, defined
Prognostic factors Total (%) as time from surgery to death.
Statistical analyses were carried out on the softwareNumber of patients 350
Median age (years) 65 package Stata [9]. Survival percentages over time have
been calculated according to the Kaplan–Meier method
FIGO stage: [10], and their corresponding standard errors (SEs) with
IA 67 (19) Greenwood’s formula [11]. For the univariate analysis theIB 186 (53)
P values from the log-rank test are reported [12]. Esti-IC 97 (28)
mated hazard ratios (HR) for DFS and OS, their 95%
Differentiation: confidence intervals (95% Cl) and P values were calcu-
G1 166 (47.5) lated with a multivariate proportional hazard-regression
G2 123 (35)
model [13]. Appropriate binary indicators have beenG3 61 (17.5)
defined to identify the categories of the following vari-
ables: age (50, 51–60, 61–70, 71), FIGO stage IA–IC,
grades 1–3. Variables describing duration and intensity of
versitaire Vaudois, Lausanne, Switzerland. Patients charac- radiation therapy have not been considered given the
teristics are summarized in Table 1. The median age was homogeneity of treatment delivered. HRs quoted in the
65 years (range 36–86 years). The tumors were classified Section 3 are from a model including all above variables.
in three grades: well (G1), moderately (G2) or poorly Values of HR greater than unity indicate increased rates of
(G3), according to the WHO cellular differentiation [5]. any of the events contributing to death (or of death for OS)
Slides were reviewed by two pathologists. with respect to the chosen reference category (for which
HR51 by definition). The probability that local progres-
2.2. Treatment sion or metastasis or death occurs before any specified
time has been estimated by means of cumulative incidence
All patients underwent total extrafascial hysterectomy functions [14]. For the sake of interpretation we point out
and bilateral salpingo-oophorectomy. Postoperative treat- that one minus the sum of such probabilities (local relapse,
ment strategy was planned on the pathology report of the metastasis, death), at any given point in time, corresponds
myometrial invasion only, independently of the cellular to the probability of being alive and disease-free as
differentiation. Peritoneal washing was not routinely ob- obtained from the Kaplan–Meier estimate of the DFS.
tained and lymph nodes dissection was very uncommon. Appropriate statistical methods have been used for com-
All 350 patients received vaginal vault irradiation. In paring cumulative incidences allowing for stratification
addition 56/186 patients with stage IB greater than 30% factors [15]. All probability values are for two-sided tests.
myometrial infiltration, and all 97 patients with stage IC For the purpose of the analyses, observations have been
received external irradiation. censored at 5 years in order to limit the effect of
competing causes of mortality and also to avoid having
2.3. Radiation therapy only patients registered during the earlier periods contrib-
ute to the right tail of the curves.
Four weeks after surgery, external irradiation was given
on the pelvic volume with a linear accelerator (6–18 MeV)
for a total dose of 4500 cGy fractionated at a daily dose of 3. Results
180–200 cGy [6–8]. The reference point for dose prescrip-
tion was at the intersection of the four beams. The upper 3.1. Association among patient characteristics
limit of the pelvic volume was defined by a line passing
through the L5–S1 interspace. The lateral borders were Age was associated with tumor stage. Patients with
located 1 cm beyond the bony pelvis. The inferior border FIGO stage IA were younger (63 years) than those with
covered two-thirds of the vagina. stage IB (65 years) or stage IC (67 years) (P50.0036). No
Brachytherapy delivered a boost of 45 Gy at the surface other association among prognostic factor was found.
of the vaginal cuff over 2 weeks (three fractions) with a
137high dose-rate ( Cs) remote afterloading system. 3.2. Disease-free survival analysis
2.4. Statistical methods The median follow-up was in excess of 7 years. As
explained in Section 2, DFS and OS have been censored at
The primary endpoint of this retrospective study was 5 years. A total of 55 events have been observed by the
disease-free survival (DFS), which was defined as time fifth year. The 5-year DFS was 8068%. When considering
from surgery to the first of the three competing events: sub-groups, the 5-year DFS was 8863% for the G1 group,
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Table 37764% for the G2 group, and 67.7% for the G3 group
aCumulative incidences (%) of three events contributing to DFS(P50.0049). In terms of multivariate hazard ratio (HR),
Grade Local relapse Metastasis Deaththe relative difference between the three groups corre-
sponds to an increase of 77% of the risk of occurrence of 1 4.6 1.4 6.0
either of the three events considered (local relapse, metas- 2 9.0 6.3 7.9
3 4.6 7.2 20.7tasis and death) (HR51.77, 95% Cl [0.94–3.33]) (P5
P value 0.027 ,0.001 ,0.0010.078) for the G2 group, and of 163% (HR52.63, 95% Cl
a Standard errors are in all cases less than 3%. The reported P value are[1.27–5.43]) (P50.009) for the G3 group with respect to
from an adjusted test, stratifed by FIGO stage.G1 group. These and additional multivariate results are
displayed in Table 2. Local relapse was defined as vaginal
and/or latero-pelvic recurrence. 3.4. Overall survival analysis
The 5-year overall survival was 84.862%. When consid-
3.3. Cumulative incidence analysis ering sub-groups, the 5-year OS was 9163% for the G1
group, 8364% for the G2 group, and 67.7% for the G3
In order to better investigate the effect of grade on the group (P50.0018). In terms of multivariate hazard ratio
pattern of occurrence of the events contributing to DFS (HR), the relative difference between the three groups
(local relapse, metastasis and death), we have estimated the corresponds to a non-significant increase of 51% of the
cumulative incidence of each of these competing events risk of death for the G2 group (HR51.51, 95% Cl [0.71–
individually. The results are summarized in Table 3. With 3.19]) (P50.282), and of 237% for the G3 group (HR5
regard to cell differentiation, the 5-year cumulative per- 3.37, 95% Cl [1.52–7.44]) (P50.003) with respect to the
centage of local relapses was 4.6% for grade 1, 9.0% for G1 group (Table 2).
grade 2, and 4.6% for grade 3 (P50.027). Similarly, such
percentages were 1.4, 6.3 and 7.2% (P,0.001) for metas-
tasis, and 6.0, 7.9 and 20.7% (P,0.001) for deaths. The 4. Discussion
cumulative incidence curves are displayed in Figs. 1–3.
Fig. 1 for local recurrence shows a rapid increase of the Our study confirms the prognostic importance of cell
curve of the grade 2 tumors during the first year after differentiation on disease-free survival (DFS) and overall
treatment, and a slower increase and subsequent leveling survival (OS) of adenocarcinoma of the endometrium. The
off of the curves in the G1 and G3 groups by the third relative shapes of the cumulative incidence curves suggest
year. Fig. 2 for distant metastasis shows a slow increase that the strong reduction in DFS beyond the first year after
and subsequent levelling off of the curves in the G2 and treatment for patients with G3 differentiation can be
G3 groups at three years. As concern deaths, Fig. 3 attributed to death. As in other series, well-differentiated
suggests that they continue to accumulate over time in all (G1) tumors were easily locally controlled, resulting in a
differentiation groups, but again much faster for G3. The longer survival. In contrast, moderately (G2) and poorly
5-year percentage of deaths is almost triple compared to (G3) differentiated tumors were characterised by metas-
what has been observed in the G1 and G2 groups. tases and death, respectively [1,16–22]. G2 patients pro-
Table 2
Cox’s analysis fitted to the overall survival (OS) and disease-free survival (DFS)
OS P value DFS P value
HR (95% CI) HR (95% CI)
Age (years):
50 Reference category Reference category
51–60 1.85 (0.21–16.85) 0.577 0.86 (0.16–4.77) 0.871
61–70 2.51 (0.33–19.05) 0.371 1.77 (0.41–7.57) 0.438
70 4.86 (0.64–36.45) 0.124 3.22 (0.76–13.67) 0.112
FIGO stage:
I Reference category Reference category
II 0.99 (0.36–2.73) 0.996 0.71 (0.31–1.64) 0.430
III 2.20 (0.82–5.89) 0.116 1.84 (0.83–4.09) 0.130
Grade:
1 Reference category Reference category
2 1.51 (0.71–3.19) 0.282 1.77 (0.94–3.33) 0.078
3 3.37 (1.52–7.44) 0.003 2.63 (1.27–5.43) 0.009
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Fig. 3. Cumulative percentages of death according to differentiation.
Fig. 1. Cumulative percentages of local relapse according to differentia-
tion. gressed at a relatively slow pace, possibly allowing for the
detection of local relapse and metastases. On the other
hand G3 patients, in whom a high mortality has been
observed as opposed to a low rate of local or distant
metastases, were probably prone to a rather fast disease
progression, in which only the final stage of the evolution,
death, was unfortunately detected.
Factors associated with the high grade histological
variant that may have a bearing on prognosis include a
tendency for higher mean age at diagnosis, a greater
incidence of both deep myometrial invasion and lymph
node involvement [3], and a high risk of clinical understag-
ing as well as a higher rate of vaginal recurrences [4]. Age
at diagnosis did not appear as a significant prognostic
factor, though for both OS and DFS the estimated HRs
showed a trend in the expected direction. This contrasts
with other papers showing that age has a prognostic impact
[18,23]. Our small number of events might not have
allowed us to detect this effect, possibly of small mag-
nitude. One might not exclude a bias in the results due to
competing causes of death especially acting in older age
groups. Our observations cover a time span of over 15
years during which cause of death attribution has not been
performed systematically and according to consistent
standards. Even if cause of death was available for all
patients, we would question its precision and especially so
for older patients. Additionally, the focus of the report is
Fig. 2. Cumulative percentages of metastases according to differentiation. on tumor grade, which was not significantly associated
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